Data / Drug companies / Oseltamivir phosphate
Oseltamivir phosphate: 37 companies and 109 products in the FDA NDC directory
Oseltamivir phosphate is listed in the FDA National Drug Code Directory by 37 companies, with 109 products in commercial distribution. 106 of the products (97.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; powder, for suspension; for suspension, and the newest product started marketing on October 9, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 37
- Products
- 109
- Generic (ANDA) products
- 106 (97.2%)
- Application numbers
- 31
- Routes
- Oral
- Brand names
- Tamiflu, Oseltamivir
- openFDA record search
- api.fda.gov
Companies that list oseltamivir phosphate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 7 | capsule; powder, for suspension | Generic drugs (ANDA) | July 13, 2023 |
| Proficient Rx LP | 7 | capsule; powder, for suspension | Generic drugs (ANDA) | October 5, 2018 |
| Preferred Pharmaceuticals Inc. | 6 | capsule; for suspension | Generic drugs (ANDA) | January 28, 2026 |
| Sportpharm LLC | 6 | capsule | Generic drugs (ANDA) | October 8, 2018 |
| Asclemed USA, Inc. | 5 | capsule; powder, for suspension | Generic drugs (ANDA) | October 5, 2018 |
| Alvogen Inc. | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | November 1, 2017 |
| Camber Pharmaceuticals, Inc. | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | March 28, 2022 |
| Epic Pharma, LLC | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | August 2, 2022 |
| Exelan Pharmaceuticals Inc. | 4 | capsule; for suspension | Generic drugs (ANDA) | December 1, 2023 |
| Lannett Company, Inc. | 4 | capsule; suspension | Generic drugs (ANDA) | July 13, 2023 |
| Lupin Pharmaceuticals, Inc. | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | February 21, 2018 |
| Novadoz Pharmaceuticals LLC | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | May 6, 2022 |
| Redpharm Drug | 4 | capsule | Generic drugs (ANDA) | May 15, 2023 |
| Strides Pharma Science Limited | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | October 24, 2022 |
| Zydus Pharmaceuticals USA Inc. | 4 | capsule; for suspension | Generic drugs (ANDA) | September 14, 2017 |
| Genentech, Inc. | 3 | capsule; powder, for suspension | New drug applications (NDA) | March 21, 2011 |
| Laurus Labs Limited | 3 | capsule | Generic drugs (ANDA) | May 2, 2024 |
| Macleods Pharmaceuticals Limited | 3 | capsule | Generic drugs (ANDA) | September 21, 2017 |
| Remedyrepack Inc. | 3 | capsule | Generic drugs (ANDA) | October 9, 2026 |
| Shandong New Time Pharmaceutical Co., Ltd. | 3 | capsule | Generic drugs (ANDA) | July 9, 2025 |
| Zhejiang Poly Pharm. Co., Ltd. | 3 | capsule | Generic drugs (ANDA) | December 31, 2025 |
| Zydus Lifesciences Limited | 3 | capsule | Generic drugs (ANDA) | February 24, 2017 |
| NuCare Pharmaceuticals,Inc. | 2 | powder, for suspension; for suspension | Generic drugs (ANDA) | May 28, 2020 |
| Proficient Rx LP | 2 | capsule | Generic drugs (ANDA) | August 25, 2020 |
| Ajanta Pharma USA Inc. | 1 | for suspension | Generic drugs (ANDA) | May 28, 2020 |
| Alembic Pharmaceuticals Inc. | 1 | for suspension | Generic drugs (ANDA) | June 29, 2026 |
| Alembic Pharmaceuticals Limited | 1 | for suspension | Generic drugs (ANDA) | June 29, 2026 |
| Amneal Pharmaceuticals NY LLC | 1 | for suspension | Generic drugs (ANDA) | March 5, 2018 |
| Aurobindo Pharma Limited | 1 | powder, for suspension | Generic drugs (ANDA) | May 10, 2024 |
| AvKARE | 1 | for suspension | Generic drugs (ANDA) | August 26, 2019 |
| Cipla USA Inc. | 1 | for suspension | Generic drugs (ANDA) | January 16, 2023 |
| Hec Pharm USA Inc. | 1 | suspension | Generic drugs (ANDA) | March 25, 2026 |
| Leading Pharma, LLC | 1 | suspension | Generic drugs (ANDA) | June 1, 2022 |
| MSN Laboratories Private Limited | 1 | capsule | Generic drugs (ANDA) | May 22, 2020 |
| Oryza Pharmaceuticals Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | October 19, 2025 |
| Slate Run Pharmaceuticals, LLC | 1 | capsule | Generic drugs (ANDA) | January 1, 2024 |
| Teva Pharmaceuticals USA, Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | July 10, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 79 | 72.5% |
| Powder, for suspension | 15 | 13.8% |
| For suspension | 11 | 10.1% |
| Suspension | 4 | 3.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 106 | 97.2% |
| New drug applications (NDA) | 3 | 2.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Neuraminidase Inhibitor | 106 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.